1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, Korea.
2Health Insurance Review and Assessment Service, Seoul, Korea.
3Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
4Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
5Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
6Division of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
7Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Copyright © 2015 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.
HR | 95% CI | P value | |
---|---|---|---|
Total | 1.91 | 1.63-2.22 | <0.001 |
Pioglitazone | 1.85 | 1.34-2.53 | 0.001 |
Sitagliptin | 2.00 | 1.60-2.49 | <0.001 |
Vildagliptin | 1.79 | 1.32-2.41 | 0.001 |
Characteristic | Total | Pioglitazone | Sitagliptin | Vildagliptin |
---|---|---|---|---|
Number | 935,519 (100) | 233,790 (25.0) | 481,245 (51.4) | 220,484 (23.6) |
Age, yr | 59.4±10.1 | 59.9±10.1 | 59.2±10.1 | 59.4±10.1 |
Sex, male/female | 518,614/416,905 | 130,936/102,854 | 265,144/216,101 | 122,534/97,950 |
Follow-up, day | 336.8±354.3 | 333.2±361.6 | 340.9±356.0 | 331.7±342.5 |
Event | Incidence rates/100,000 patient-yr | ||||
---|---|---|---|---|---|
Total | 0-360, day | 0-30, day | 31-360, day | ||
Total | 998 | 115.7 | 130.7 | 222.4 | 116.7 |
Pioglitazone | 251 | 117.7 | 132.5 | 219.7 | 118.7 |
Sitagliptin | 475 | 105.7 | 119.6 | 211.6 | 105.7 |
Vildagliptin | 272 | 135.8 | 153.4 | 249.1 | 138.9 |
HR | 95% CI | P value | |
---|---|---|---|
Total | 1.91 | 1.63-2.22 | <0.001 |
Pioglitazone | 1.85 | 1.34-2.53 | 0.001 |
Sitagliptin | 2.00 | 1.60-2.49 | <0.001 |
Vildagliptin | 1.79 | 1.32-2.41 | 0.001 |
Period | Drugs | HR | 95% CI | P value |
---|---|---|---|---|
0-360, day | Pioglitazone | 1 | ||
Sitagliptin | 0.97 | 0.80-1.16 | 0.715 | |
Vildagliptin | 1.22 | 0.99-1.50 | 0.066 | |
0-30, day | Pioglitazone | 1 | ||
Sitagliptin | 1.02 | 0.69-1.49 | 0.931 | |
Vildagliptin | 1.19 | 0.77-1.84 | 0.441 | |
31-360, day | Pioglitazone | 1 | ||
Sitagliptin | 0.95 | 0.77-1.18 | 0.643 | |
Vildagliptin | 1.22 | 0.97-1.55 | 0.094 |
Values are presented as number (%) or mean±standard deviation.
HR, hazard ratio; CI, confidence interval.
Adjusted for age and sex. HR, hazard ratio; CI, confidence interval.